Royal Bank of Canada Has Lowered Expectations for Inovio Pharmaceuticals (NASDAQ:INO) Stock Price

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) had its price objective lowered by research analysts at Royal Bank of Canada from $6.00 to $5.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank of Canada's target price suggests a potential upside of 160.42% from the company's previous close.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reissued a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday. JMP Securities restated a "market outperform" rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Inovio Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $12.20.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock traded down $0.02 during trading on Wednesday, hitting $1.92. The company's stock had a trading volume of 2,019,265 shares, compared to its average volume of 550,650. The stock has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.48 and a beta of 0.92. The stock's fifty day moving average is $2.04 and its 200 day moving average is $3.67. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75.

Remove Ads

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.18. The firm had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.03 million. On average, research analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INO. FMR LLC increased its stake in Inovio Pharmaceuticals by 370.1% during the 3rd quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company's stock worth $158,000 after buying an additional 21,462 shares during the period. BNP Paribas Financial Markets increased its stake in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 3,630 shares during the period. MetLife Investment Management LLC increased its stake in Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 8,546 shares during the period. Atom Investors LP purchased a new stake in Inovio Pharmaceuticals during the 3rd quarter worth $103,000. Finally, State Street Corp increased its stake in Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock worth $2,836,000 after buying an additional 51,414 shares during the period. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.